INTRODUCTION {#S1}
============

The Ca^2+^/calmodulin-dependent protein kinase II (CaMKII) and the death-associated protein kinase 1 (DAPK1) are both members of the CaM kinase family (reviewed in [@R6]). Both bind to the NMDA-type glutamate receptor (NMDAR) subunit GluN2B but with opposing physiological consequences: although CaMKII binding is required for normal long-term potentiation (LTP) ([@R5]; [@R18]), DAPK1 instead mediates the opposing form of synaptic plasticity, long-term depression (LTD) ([@R15]). Indeed, the DAPK1 function in LTD is the suppression of CaMKII/GluN2B binding, and binding of DAPK1 and CaMKII to GluN2B is competitive ([@R15]), consistent with overlapping binding sites on GluN2B (see [Figure 1A](#F1){ref-type="fig"}). However, this mutually exclusive competitive binding also raises an apparent conundrum, because GluN2B binding of each kinase has been suggested to mediate excitotoxic neuronal cell death: binding of DAPK1 in an *in vivo* mouse model of stroke ([@R43]) and binding of CaMKII in neuronal culture models ([@R47]). Overlapping binding sites on GluN2B also raised the possibility that the neuroprotective GluN2B-derived peptide that was designed to displace DAPK1 from GluN2B (tatN2Bc; [@R43]) could additionally interfere with CaMKII binding. Vice versa, the neuroprotective mutations designed to disrupt the CaMKII/GluN2B binding ([@R40]; [@R47]) could potentially additionally disrupt DAPK1 binding. Thus, although there is ample indication for the general involvement of both CaMKII and DAPK1 in ischemic neuronal cell death ([@R10]; [@R11]; [@R31]; [@R38]; [@R44]; [@R46]), it is currently not clear which one of these two CaM kinases really needs to specifically bind to GluN2B during the process. Additionally, a recent study questioned any involvement of DAPK1 in ischemic cell death at all ([@R25]). Here, we set out to clarify the roles of CaMKII and DAPK1 and their respective binding to GluN2B in ischemic neuronal cell death.

Our *in vivo* mouse model for global cerebral ischemia closely resembles the most prevalent human condition: the ischemic cell death that occurs after cardiac arrest followed by cardiopulmonary resuscitation (CA/CPR). As with focal cerebral ischemia during stroke, neuronal cell death after global cerebral ischemia is thought to be induced largely by excitotoxicity, i.e., by NMDAR overstimulation caused by the massive release of the excitatory neurotransmitter glutamate during anoxic depolarization ([@R24]; [@R36]; [@R41]).

Here, we show that the GluN2B^ΔCaMKII^ mutation (L1298A/R1300Q; [@R4]; [@R18]) dramatically reduced hippocampal neuronal cell death after global cerebral ischemia induced *in vivo* by CA/CPR. Importantly, the GluN2B^ΔCaMKII^ mutation abolished GluN2B binding for CaMKII but did not affect DAPK1. Additionally, we tested the effect of excitotoxic or ischemic insults on synaptic trafficking and GluN2B binding of CaMKII versus DAPK1. Together, our results demonstrate that CaMKII binding to synaptic GluN2B mediates ischemic neuronal cell death and suggest that any involvement of DAPK1 binding is restricted to extra-synaptic GluN2B.

RESULTS {#S2}
=======

The GluN2B^ΔCaMKII^ Mutation Provides Neuroprotection after Cardiac Arrest {#S3}
--------------------------------------------------------------------------

The GluN2B^ΔCaMKII^ mutation combines two point mutations (L1298A and R1300Q) within the shared binding region for DAPK1 and CaMKII ([Figure 1A](#F1){ref-type="fig"}). CaMKII inhibition or T286A mutation strongly protects neurons from the ischemic cell death that is induced by CA/CPR *in vivo* ([@R11]). Here, we tested the effect of the GluN2B^ΔCaMKII^ mutation. Cardiac arrest was induced in wild-type (WT) and homozygous mutant mice by KCl injection; after 6 min, mice were resuscitated with epinephrine injection, oxygen supply, and chest compressions ([Figure 1B](#F1){ref-type="fig"}). Neuronal cell death was assessed by H&E staining 3 days after CA/CPR, specifically in hippocampal CA1 neurons ([Figure 1C](#F1){ref-type="fig"}), one of the most vulnerable neuron populations during global cerebral ischemia ([@R22]; [@R28]; [@R37]). Compared to their WT littermates, GluN2B^DCaMKII^ mutant mice were significantly protected from neuronal cell death ([Figure 1D](#F1){ref-type="fig"}).

In cortex and cerebellum, only minimal damage was observed here, even in WT mice of our cohort that showed significant hippocampal damage in CA1 ([Figure S1](#SD1){ref-type="supplementary-material"}). Although consistent with the special vulnerability of CA1, it should be noted that prolonged global cerebral ischemia can cause neuronal cell death also in other brain areas ([@R32]), including in the cerebellum after prolonged CA/CPR ([@R33]).

The GluN2B^ΔCaMKII^ Mutation Abolishes Binding of CaMKII {#S4}
--------------------------------------------------------

Each of the two point mutations that are combined in the GluN2B^ΔCaMKII^ mutant individually reduce CaMKII/GluN2B binding ([@R40]). Although the combined mutation was likely to be additive, the effects of this combined mutation have not been directly tested. Binding was tested here first using an established *in vitro* micro-titer plate binding assay using purified recombinant proteins ([@R3]; [@R7]). As expected, this double mutation abolished CaMKII/GluN2B binding almost completely ([Figure 1E](#F1){ref-type="fig"}). Next, we tested how the GluN2B^ΔCaMKII^ mutation affects CaMKII binding to GluN2B within a cellular environment; this utilized an established colocalization assay in HEK293 cells after co-expression of mCherry-CaMKII and EGFP fused to a membrane-localization sequence and the GluN2B C-terminal tail (GluN2Bc; residues 1,120--1,482; note that this GluN2B fusion protein localizes also to intra-cellular membranes of organelles, such as the endoplasmic reticulum; [@R15]). CaMKII binding to GluN2B requires CaMKII activation (either by Ca^2+^/CaM or by T286 phosphorylation; [@R7]; [@R29]; [@R40]); thus, as expected, CaMKII did not colocalize with either WT or mutant GluN2Bc under basal conditions ([Figures 1F](#F1){ref-type="fig"} and [1G](#F1){ref-type="fig"}). After imaging baseline localization, cells were stimulated with 10 μM ionomycin to induce Ca^2+^ influx and were imaged again at 2.5 and 5 min. After ionomycin stimulation, a robust translocation of CaMKII to GluN2Bc was observed for WT, but not for the GluN2B^ΔCaMKII^ mutation ([Figures 1F](#F1){ref-type="fig"} and [1H](#F1){ref-type="fig"}). Thus, as expected, the GluN2B^ΔCaMKII^ mutation indeed effectively disrupts CaMKII/ GluN2B binding, both *in vitro* and within cells.

The GluN2B^ΔCaMKII^ Mutation Does Not Affect Binding of DAPK1 {#S5}
-------------------------------------------------------------

In contrast to CaMKII/GluN2B binding, the DAPK1/GluN2B binding was unaffected by the GluN2B^ΔCaMKII^ mutation ([Figures 1I](#F1){ref-type="fig"}--[1L](#F1){ref-type="fig"}). The binding was first tested in an *in vitro* pull-down assay using DAPK1 from HEK293 cell extracts after DAPK1 overexpression ([Figure 1I](#F1){ref-type="fig"}). Note that Ca^2+^/CaM disrupts the DAPK1/ GluN2B binding ([@R15]); thus, Ca^2+^/CaM was not included in the *in vitro* binding assays with DAPK1. Additionally, we assessed DAPK1/GluN2B binding within HEK293 cells after co-expression of mCherry-DAPK1 and EGFP-GluN2Bc. As reported previously ([@R15]), DAPK1 basally localized with GluN2Bc; consistent with the *in vitro* binding assay, this basal localization was not affected by the GluN2B^ΔCaMKII^ mutation ([Figures 1J](#F1){ref-type="fig"} and [1K](#F1){ref-type="fig"}). Upon ionomycin treatment to induce a Ca^2+^ stimulus, DAPK1 dispersed to equal extent from GluN2Bc WT and the GluN2B^ΔCaMKII^ mutant ([Figures 1J](#F1){ref-type="fig"} and [1L](#F1){ref-type="fig"}). Thus, the GluN2B^ΔCaMKII^ mutation does not affect the DAPK1/GluN2B binding or its disruption by Ca^2+^ stimuli.

Neuroprotective Inhibitors of CaMKII and DAPK1 Do Not Cross-React {#S6}
-----------------------------------------------------------------

Although our results directly demonstrate that CaMKII/GluN2B binding is involved in ischemic cell death, they do not rule out a potential additional involvement of DAPK1. Notably, DAPK1 involvement has been controversial: although one study described a specific requirement for DAPK1/GluN2B binding in ischemic cell death ([@R43]), a more recent study questioned any DAPK1 involvement whatsoever ([@R25]). Thus, we decided to determine the selectivity of demonstrated neuroprotective peptides in preventing CaMKII versus DAPK1 binding to GluN2B, using our *in vitro* binding assays ([Figure 2A](#F2){ref-type="fig"}). The CaMKII inhibitor peptide tatCN21 (which binds to CaMKII at the same site as GluN2B; [@R45]) specifically interfered with GluN2B binding of CaMKII, but not DAPK1. More importantly, the tat2B peptide (which is derived from the binding site on GluN2B and shown to disrupt DAPK1/GluN2B binding *in vivo*; [@R43]) instead specifically interfered with GluN2B binding of DAPK1, but not CaMKII ([Figure 2A](#F2){ref-type="fig"}). Thus, neuroprotection by tat2B is not mediated by off-target effects on CaMKII (although it may instead be due to off-target effects on NMDAR function; [@R25]).

TC-DAPK-6 (TC-6) is a small molecule inhibitor of DAPK1 that is ATP competitive and thus expected to interfere only with enzymatic DAPK1 activity, not GluN2B binding. Indeed, TC-6 did not interfere with GluN2B binding of either kinase ([Figure 2A](#F2){ref-type="fig"}) and did not interfere with activity of CaMKII ([Figure 2B](#F2){ref-type="fig"}).

Excitotoxic CaMKII Movement to Dendritic Spines Is Mediated by GluN2B Binding {#S7}
-----------------------------------------------------------------------------

Biochemical fractionation indicated that CaMKII further accumulates in synaptosomes after GCI induced by CA/CPR ([@R11]). Here, we first used expression of YFP-CaMKII in order to live-monitor its accumulation in hippocampal neurons exposed to excitotoxic glutamate stimuli ([Figures 3A](#F3){ref-type="fig"} and [S2A](#SD1){ref-type="supplementary-material"}). As expected, YFP-CaMKII quickly accumulated at excitatory dendritic spine synapses (identified by morphology and by the marker protein PSD95), but not at inhibitory synapses (identified by the marker protein gephyrin). In order to monitor the movement also for endogenous CaMKII, we used our recently described FingR intrabody-based method for simultaneous live imaging of three endogenous proteins, specifically for CaMKII and the two synaptic marker proteins PSD95 and gephyrin ([@R9]). As expected, endogenous CaMKII also accumulated at excitatory dendritic spine synapses ([Figures 3B](#F3){ref-type="fig"} and [S2B](#SD1){ref-type="supplementary-material"}). Here, the live-imaging method was adapted for use in mouse neurons, in order to monitor endogenous CaMKII movement also in transgenic neurons. Importantly, the CaMKII movement to excitatory synapses in response to excitotoxic insults was abolished in neurons from the GluN2B^ΔCaMKII^ mutant mice ([Figures 3C](#F3){ref-type="fig"} and [S2C](#SD1){ref-type="supplementary-material"}). Thus, like the CA/CPR-induced neuronal cell death, CaMKII movement to excitatory synapses during excitotoxic insults requires CaMKII/GluN2B binding.

DAPK1 Dispersal from Dendritic Spines May Promote Binding to Extra-synaptic GluN2B {#S8}
----------------------------------------------------------------------------------

In contrast to CaMKII, mCherry-DAPK1 was highly basally enriched at excitatory dendritic spine synapses but then quickly dispersed in response to excitotoxic glutamate stimuli ([Figures 4A](#F4){ref-type="fig"} and [S2D](#SD1){ref-type="supplementary-material"}). As no intrabody is available for DAPK1, movement of endogenous DAPK1 was instead monitored by biochemical fractionation ([Figures 4B](#F4){ref-type="fig"} and [S3A](#SD1){ref-type="supplementary-material"}). Consistent with our imaging results, CaMKII accumulated in a crude synaptic fraction after excitotoxic glutamate simulation although DAPK1 instead moved out ([Figure 4B](#F4){ref-type="fig"}); however, although DAPK1 dispersal from synapses was apparent immediately, it only became statistically significant at later time points ([Figure 4B](#F4){ref-type="fig"}). These results strongly suggest that excitotoxic stimuli do enhance only CaMKII, but not DAPK1, binding to synaptic GluN2B.

Next, we decided to examine the effect of our CA/CPR *in vivo* injury model on the movement of CaMKII versus DAPK1 among the hippocampal synaptic versus extra-synaptic fractions ([Figures 4C](#F4){ref-type="fig"} and [S3A](#SD1){ref-type="supplementary-material"}). Consistent with our cell culture model, the crude synaptic fraction showed an increase in CaMKII and decrease in DAPK1; corresponding opposite changes were detected in the extra-synaptic fractions ([Figures 4C](#F4){ref-type="fig"} and [S3A](#SD1){ref-type="supplementary-material"}). Interestingly, GluN2B was found basally mainly in the synaptic fraction, and CA/CPR caused a further sharp decrease in extra-synaptic GluN2B ([Figure 4D](#F4){ref-type="fig"}); a similar effect was also seen after excitotoxic glutamate treatments *in vitro* ([Figure S3B](#SD1){ref-type="supplementary-material"}). However, consistent with a previous report ([@R43]), co-immunoprecipitation experiments indicated an increased relative association of DAPK1 with this overall decreased extra-synaptic pool of GluN2B ([Figures S3C](#SD1){ref-type="supplementary-material"} and [S3D](#SD1){ref-type="supplementary-material"}).

Together, our data indicate that CaMKII binding to synaptic GluN2B is required for neuronal cell death after ischemia, whereas a potential role of DAPK1 binding is restricted to a decreasing extra-synaptic GluN2B population.

DISCUSSION {#S9}
==========

DAPK1 binding to the NMDA-receptor subunit GluN2B has been prominently indicated to mediate ischemic neuronal cell death *in vivo* ([@R43]). However, here, we provide direct genetic evidence showing instead a requirement for CaMKII binding. This posed a conundrum, as DAPK1 and CaMKII binding occurs at overlapping sites on GluN2B (see [Figure 1A](#F1){ref-type="fig"}) and is mutually exclusive ([@R15]). Clearly, only one of the two kinases can bind to a single GluN2B molecule at a time. After the genetic demonstration of CaMKII involvement here, this left several possible explanations: (1) neuroprotective DAPK1 inhibitors may show non-selective interference also with the related CaMKII. However, such cross reactions were not detected here. (2) Binding of both CaMKII and DAPK1 to GluN2B could increase, just on different GluN2B molecules. However, this would require that the binding sites do not get saturated, which appears highly unlikely given the stoichiometric excess of the kinases over the receptor ([@R12]; [@R23]). (3) Finally, the kinases may bind to principally distinct GluN2B populations. Indeed, our imaging studies showed that excitotoxic insults cause CaMKII accumulation in dendritic spines but dispersal of DAPK1 away from these sites of excitatory synapses. Furthermore, the CaMKII accumulation required GluN2B binding (as it was abolished by the binding-incompetent GluN2B^ΔCaMKII^ mutant). Consistent with a previous report ([@R43]), there may also be an increased association of DAPK1 with GluN2B, but this is restricted to the extra-synaptic fraction. A synaptic PSD fraction has not been tested for either DAPK1 or CaMKII association with GluN2B, as this would not be very informative: the PSD forms a large protein complex, and co-precipitation would not indicate direct interaction. However, our imaging studies clearly show that DAPK1 does not accumulate at the PSD but instead disperses from its basal colocalization with the marker protein PSD95. Taken together, our data show that CaMKII and DAPK1 associate with different pools of GluN2B after excitotoxic stimuli. Thus, although the competitive mutually exclusive binding of either CaMKII or DAPK1 to synaptic GluN2B participates in determining the direction of physiological synaptic plasticity (i.e., LTP versus LTD; [@R15]), excitotoxic insults instead involve increased CaMKII binding to synaptic GluN2B and DAPK1 binding to extra-synaptic GluN2B.

Notably, it has been suggested that extra-synaptic NMDARs mediate neuronal cell death, whereas synaptic NMDARs instead promote neuronal survival ([@R20]; [@R21]). This has also been coupled with the notion of differential NMDAR subunit localization, with largely extra-synaptic GluN2B versus largely synaptic GluN2A. However, most NMDARs in the adult hippocampus are now recognized to be triheteromeric (containing GluN1, GluN2B, and GluN2A; [@R19]; [@R35]; [@R42]), and our results clearly demonstrate a role for synaptic GluN2B in ischemia, at least as synaptic targeting protein for CaMKII, if not as the required Ca^2+^ source. Additionally, the neuroprotection provided by synaptic SK channels ([@R1]) is most easily explained by a negative feedback on synaptic NMDARs. Thus, although our results do not rule out a function of extra-synaptic NMDARs in ischemia, they do demonstrate a function of synaptic NMDARs.

Although our findings indicate increased extra-synaptic DAPK1/GluN2B interaction, this does not necessitate functional requirement, and a recent study has seriously questioned any involvement of DAPK1 in ischemic cell death at all ([@R25]). This is in contrast to other previous studies that do support a role for DAPK1, even if most of them did not specifically investigate the DAPK1 binding to GluN2B ([@R31]; [@R38]; [@R43]; [@R44]). Notably, although the involvement of DAPK1 in ischemia may be subject to further debate, the results and claims of our current study would remain consistent with either conclusion. By contrast, for the CaMKII/GluN2B interaction, our data directly indicate a functional role in ischemic cell death.

No efficient pharmacological treatment is clinically available for any excitotoxic conditions (including stroke and global cerebral ischemia), emphasizing the importance of understanding the underlying signal transduction mechanisms ([@R17]; [@R34]). Tremendous but unsuccessful efforts have been made in the development of a stroke therapy, even though global cerebral ischemia may provide a more amenable condition for therapeutic intervention, in part due to a more homogeneous patient population with full reperfusion of the injured brain regions within a well-defined time period. Our previous studies have indicated the potential for pharmacological success of CaMKII inhibition, at least in mouse models of stroke ([@R46]), and of the potentially more promising global cerebral ischemia ([@R11]). The current study provides further target validation by genetic means. Notably, other previous genetic studies appeared conflicting: although CaMKII T286A mutation was protective in global cerebral ischemia ([@R11]), complete knockout of the brain-specific CaMKIIα isoform instead enhanced injury in a stroke model ([@R48]). This could be due to fundamental difference in the injury models or in the effects of specific kinase functions. Indeed, complete loss of CaMKII may sensitize to cell death, although block of over-activated "autonomous" CaMKII after ischemia may be protective ([@R2]; [@R10]). Notably, autonomous CaMKII activity can be generated by both T286 phosphorylation and GluN2B binding ([@R7]; [@R6]; [@R26]). But why are both forms of autonomy required for cell death yet with protection achieved by abolishing just one? A similar situation actually appears to be the case for the physiological induction of normal LTP, which also requires both T286 phosphorylation and GluN2B binding ([@R5]; [@R14]; [@R18]). Then, a more important question may be this: if ischemic injury is sensitive to so many different individual manipulations in mice, why are we still lacking a therapy in humans? Perhaps the answer will emerge as we shift the focus of clinical efforts from stroke to global cerebral ischemia, with the latter holding more promise for successfully measuring outcome improvements in patients.

STAR⋆METHODS {#S10}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S11}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, K. Ulrich Bayer (<ulli.bayer@ucdenver.edu>). This study did not generate new unique reagents.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S12}
--------------------------------------

### Experimental Animals {#S13}

All animal treatment was approved by the University of Colorado Institutional Animal Care and Use Committee, in accordance with NIH guidelines. Animals are housed at the Animal Resource Center at the University of Colorado Anschutz Medical Campus (Aurora, CO) and are regularly monitored with respect to general health, cage changes, and overcrowding. Pregnant Sprague-Dawley rats were supplied by Charles River Labs. Male C57BL/6 adult mice, 8 to 12 weeks old, were also supplied by Charles River Labs. The GluN2B^ΔCaMKII^ mice (L1298A/R1300Q) are described previously ([@R18]) and were kindly provided by Dr. Johannes Hell, University of California Davis. Mouse breeding is done in pairs on a C57BL/6 background, either homozygous (for culture experiments) or heterozygous (for use of littermates in CA/CPR and slice experiments).

### Primary hippocampal cultures {#S14}

Primary hippocampal neurons were imaged after 14--17 days *in vitro* (DIV14--17). Mouse cultures were prepared from P1-P2 neonatal pups of both sexes. Following decapitation and dissection, mouse hippocampi were incubated in dissociation solution (7 mL HBSS buffered saline, 150 μL 100mM CaCl~2~, 10 μL 1M NaOH, 10 μL 500mM EDTA, 200 units Papain \[Worthington\]) at room temperature for 15--30 min. After washing hippocampi in plating media (DMEM, 10% FBS, 50 units/mL pen/strep, 2 mM L-glutamine), cells were dissociated by trituration and counted. Neurons were plated on poly-D-lysine (0.1mg/mL in 1M Borate Buffer: 3.1g boric acid, 4.75 g Borax, in 1 L deionized H~2~0) and laminin (0.01mg/mL in PBS)-coated 18 mm glass coverslips in 12 well plates at a density of 150,000--200,000 cells per mL and maintained at 37°C with 5% CO~2~. After 1 day *in vitro* (DIV1), plating media was switched to feeding media (Neurobasal-A, B27 supplement, 2 mM L-glutamine). At DIV4, neurons were treated with anti-mitotic FDU (70 μM 5-fluoro-2'-deoxyuridine/140 μM uridine) to suppress glial growth. Rat cultures were prepared from P0 neonatal pups of both sexes and prepared as described previously ([@R9]); in contrast to mouse culture preparation, rat hippocampi were dissociated for 1 hour and cells were plated at 100,000 cells per mL for imaging studies and 200,000 cells per mL for biochemical studies.

### Human embryonic kidney (HEK) 293 cells {#S15}

HEK293 cells were purchased from the American Type Culture Collection (ATCC) and certified by the University of Colorado Cancer Center. Cells were maintained in DMEM supplemented with 10% FBS and penicillin/streptomycin. Cells were split and grown to 50% prior to transfection.

METHOD DETAILS {#S16}
--------------

### Material and DNA constructs {#S17}

Material was obtained from Sigma, unless noted otherwise. Expression vectors for YFP-CaMKIIα, mCh-DAPK1 (based on pEGFP) and of the GluN2B C terminus (based on pDisplay) and were described previously ([@R8]; [@R15]). The expression vectors for the GFP-labeled FingR intrabodies targeting CaMKIIα, PSD-95, and gephyrin were kindly provided by Dr. Donald Arnold (University of Southern California, Los Angeles, CA, USA) as described previously ([@R16]; [@R27]). The FingRs against PSD95 and gephyrin contained the CCR5TC repressor ([@R16]); the FingR against CaMKIIa did not contain a repressor ([@R27]). The fluorophore label was exchanged to contain the following tags in place of GFP: CaMKIIα-FingR-YFP2, PSD-95-FingR-mCh, and gephyrin-FingR-mTurquois ([@R9]). These modifications were performed using Gibson Assembly ([@R13]).

### CA/CPR {#S18}

Cardiac arrest and cardiopulmonary resuscitation (CA/CPR) was performed as previously described ([@R11]; [@R30]; [@R39]). Briefly, asystolic cardiac arrest was induced by KCl injection via jugular catheter. 6 min later, CPR was initiated by injecting 0.5--1 mL epinephrine (16 mg/mL in saline solution), chest compressions at 300/min, and ventilation with 100% O~2~. If return of spontaneous circulation was not achieved within 2 min of CPR, the animal was excluded from the study. Tissue from was collected 72 h after CA/CPR for assessment cell death in the hippocampal CA1 region.

### Cell death assays {#S19}

H&E staining of hippocampal slices was performed as previously described ([@R11]). 72 h after CA/CPR, brains were removed, post-fixed with paraformaldehyde, and embedded in paraffin. Coronal sections 6 mm thick were serially cut and stained with H&E. Three levels of the hippocampal CA1 region were analyzed (100 μm apart), beginning from 1.5 mm bregma. Nonviable neurons were determined by the presence of hypereosinophilic cytoplasm and pyknotic nuclei. The percentage of nonviable neurons was calculated for each brain region (average of three levels per region). The investigator was blinded to treatment before analyzing neuronal damage.

### Western analysis {#S20}

Protein concentration was determined using the Pierce BCA protein assay (Thermo-Fisher). Before undergoing SDS-PAGE, samples were boiled in Laemmli sample buffer for 5 min at 95°C. Proteins were separated in a resolving phase polymerized from 7%--9% acrylamide, then transferred to a polyvinylidene difluoride membrane at 24 V for 1--2 h at 4C. Membranes were blocked in 5% milk or BSA and incubated with anti-CaMKIIa (1:4000, CBa2, available at Invitrogen but made in house), pT286-CaMKII (1:2500, Phospho-Solutions), anti-GluN2B (1:1000, Cell Signaling), DAPK1 (1:800, Sigma-Aldrich), followed by either Amersham ECL goat anti-mouse HRP-linked secondary 1:10000 (GE Healthcare) or goat anti-rabbit horseradish peroxidase conjugate 1:10000 (Bio-Rad). Blots were developed using chemiluminescence (Super Signal West Femto, Thermo-Fisher), imaged using the Chemi-Imager 4400 system (Alpha-Innotech), and analyzed by densitometry (ImageJ). Variations in sample loading were corrected using b-actin (1:2000, Cell Signaling) as a loading control. Relative band intensity was normalized as a percent of control conditions on the same blot, which was set at a value of one to allow for comparison between multiple experiments.

### CaMKII and DAPK1 binding to GluN2B *in vitro* {#S21}

CaMKII and DAPK1 binding to immobilized GST-GluN2Bc (residues 1122 to 1482) was performed as described previously and detected by Western analysis of the eluted protein ([@R15]). For CaMKII binding, GST-GluN2Bc was immobilized on antiGST-coated microtiter plates ([@R7]; [@R29]); for DAPK1 binding, GST-GluN2Bc was instead immobilized on glutathione-coated magnetic beads ([@R15]).

### CaMKII and DAPK1 colocalization with GluN2B in HEK cells {#S22}

HEK culture, transfection, imaging, and analysis was performed as described previously ([@R15]). mCh-DAPK1 or mChCaMKIIα and pDisplay-eGFP-GluN2Bc (1:10) were transfected using Ca^2+^ phosphate and expressed for 16--24 hours prior to imaging. During imaging, cells were maintained in a climate-controlled chamber at 32°C in HEPES buffered imaging solution containing (in mM): 130 NaCl, 5 KCl, 20 Glucose, 2 CaCl~2~, 1 MgCl~2~, 10 HEPES pH 7.4. Images were acquired on a ZeissAxiovert 200M inverted microscope (Carl Zeiss GmbH, Oberkochen, Germany) fitted with a 63x objective (1.4NA, plan-Apo). Cells were stimulated with ionomycin (10 μM) at 1 min and imaged every 30 s over 6 min using 0.3 μm steps over 1.8 μm of the cell center. Images were deconvolved, collapsed across z-plane, and analyzed using Slidebook 6.0 software. A Pearson's correlation of fluorescent overlap for each time point was calculated using hand drawn masks encompassing the entire cell and excluding the nucleus. Raw Pearson's correlations are shown for starting values. Due to blebbing and loss of cell area, a slight but significant increase in Pearson's correlation was seen between mCh vector only control and GluN2Bc constructs. Thus, the Pearson's correlation obtained from mCh cell-fill was subtracted from data with ionomycin stimulation and the resulting value was termed "adjusted colocalization." All image analysis was done blinded to experimental condition.

### Non-radioactive kinase assay {#S23}

A kinase assay coupling the conversion of ATP to ADP during a phosphorylation event to the loss of absorbance (Abs) at 340 nM upon the oxidation of NADH to NAD by pyruvate kinase lactate dehydrogenase upon ADP accumulation was used to verify inhibitor effects on CaMKII. A reaction containing 50 mM PIPES, pH 7.12, 0.4 mM NADH, 2 mM CaCl~2~, 20 mM MgCl~2~, 2 mM Phos-phen pyruvate, 19 units of pyruvate kinase, 27.4 units of lactate dehydrogenase, 75 μM peptide substrate, 1 μM inhibitor (tatCN21 or TC-DAPK-6) and 20 nM CaMKIIα was initiated by the addition of 1 mM ATP. Abs was measured every 10 s for 10 min on a SpectraMax 340PC plate reader (Molecular Devices). All values were normalized to starting Abs for a given reaction.

### Transfection and live imaging of primary hippocampal cultures {#S24}

At 12--14 DIV, neurons were transfected with the intrabodies using a 1:1:1 ratio, at a concentration of 1 μg total DNA/well, using Lipofectamine 2000 (3 μL/well, Invitrogen) according to the manufacturer's recommendations. Two to three days following transfection (DIV 14--17), neurons were imaged using spinning disk confocal microscopy as described above and analyzed using Slidebook 6.0. During image acquisition, neurons were maintained in a climate-controlled chamber at 34°C in conditioned feeding media buffered with 5 mM HEPES, pH 7.4. Glutamate excitotoxicity was induced by treating with 100 μM glutamate for 5 min. Hippocampal neurons were selected based on pyramidal shaped soma and presence of spiny apical dendrites, and tertiary dendritic branches were selected for analysis to maintain consistency. Images were acquired before stimulation and 1 min or 5 mins after glutamate excitotoxicity. 2D maximum intensity projection images were then generated and analyzed using Slidebook 6.0. The average YFP intensity (CaMKIIα) at excitatory and inhibitory synapses was quantified using threshold masks of PSD-95 and gephyrin signal to calculate a puncta-to-shaft ratio (mean YFP intensity at PSD-95 or gephyrin puncta, divided by the mean YFP intensity of the adjacent dendritic shaft).

### Acute hippocampal slices {#S25}

Acute hippocampal slices were collected from wild-type adult mice as previously described ([@R15]). Mice were anesthetized by isoflurane and quickly decapitated. Hippocampi were dissected and sliced (400 μm) in ice-cold cutting solution (in mM: 220 sucrose, 12 MgSO~4~, 10 glucose, 0.2 CaCl~2~, 0.5 KCl, 0.65 NaH2 PO~4~, 13 NaHCO~3~, and 1.8 ascorbate) before transfer to were transferred to artificial cerebral spinal fluid (ACSF; in mM: 124 NaCl, 2 KCl, 1.3 NaH~2~PO~4~, 26 NaHCO~3~, 10 glucose, 2 CaCl~2~, 1 MgSO~4~, and 1.8 ascorbate) at 32°C. After at least 1 h recovery, slices were treated with 100 μM glutamate for 5 min and subsequently either collected or replaced with fresh ACSF for 2 h. All solutions were saturated with 95% O~2~/5% CO~2~.

### Neuronal fractionation {#S26}

Following treatment, DIV16 hippocampal neurons from rat or acute hippocampal slices from mice were homogenized as follows: To make the extra-synaptic fraction, cells were homogenized in ice-cold 1% TX100 buffer also containing (in mM): 10 Tris, 10 EDTA, 10 EGTA, 150 NaCl, plus protease and phosphatase inhibitors and cleared by ultracentrifugation (100,000 x g) for 20 min at 4°C. To make the crude synaptic fraction, the remaining insoluble pellet (including synaptosomes and lipid rafts) was solubilized in 1% SDS buffer also containing (in mM): 10 Tris, 10 EDTA, 10 EGTA, 150 NaCl, plus protease and phosphatase inhibitors, then heated at 65C for 15 min, quenched with 1.5% TX100, and cleared by centrifugation (20,000 x g) for 20 min.

### Immunoprecipitation {#S27}

After treatment, acute hippocampal slices were homogenized in TX100 to isolate the extra-synaptic fraction (described above). Cleared material was incubated on a head-over-head tilter with protein A-Sepharose beads and 2 μg of anti-GluN2B (Cell Signaling) or nonspecific rabbit immunoglobulin G (IgG, Jackson) control for 4 h at 4°C. Beads were washed three times with 0.1% Triton X-100 wash buffer also containing (in mM): 150 NaCl, 10 EDTA, 10 EGTA, 10 Tris base, pH 7.4.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S28}
---------------------------------------

All data are shown as mean ± SEM. Statistical significance is indicated in the figure legends. Statistics were performed using Prism (GraphPad) software. Imaging experiments were obtained and analyzed using SlideBook 6.0 software. Immunoblots were analyzed using ImageJ (NIH). All data were tested for their ability to meet parametric conditions, as evaluated by a Shapiro-Wilk test for normal distribution and a Brown-Forsythe test (3 or more groups) or an F-test (2 groups) to determine equal variance. All comparisons between two groups met parametric criteria, and independent samples were analyzed using unpaired, two-tailed Student's t tests. Comparisons between pre- and post-treatment images from the same neurons were analyzed using paired, two-tailed Student's t tests. Comparisons between three or more groups meeting parametric criteria were done by one-way ANOVA with specific post hoc analysis indicated in figure legends. Non-parametric data comparisons between 3 or more groups were done by Kruskal-Wallice followed by Bonferroni post hoc analysis. Comparisons to control group used Dunn's post hoc analysis.

DATA AND CODE AVAILABILITY {#S29}
--------------------------

The datasets generated during this study are available through Mendeley (<https://dx.doi.org/10.17632/5y58k87rw6.1>).
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![CaMKII Binding to GluN2B Mediates Neuronal Cell Death after Resuscitation from Cardiac Arrest\
Error bars indicate SEM in all panels.\
(A) Schematic representation of GluN2B, including the sequence of the overlapping binding region for DAPK1 and CaMKII.\
(B) Experimental timeline for the CA/CPR model of global cerebral ischemia.\
(C) Representative micrographs of the hippocampal CA1 region, with cell death visualized by H&E staining.\
(D) Quantification of neuronal cell death in the CA1 region after CA/CPR. GluN2B^DCaMKII^ mutant mice showed significantly less cell death compared to WT (\*p \< 0.05, unpaired two-tailed t test).\
(E--L) The GluN2B^ΔCaMKII^ mutation (L1298A/R1300Q) prevents binding of CaMKII, but not DAPK1.\
(E) The GluN2B^ΔCaMKII^ mutation blocks the Ca^2+^/CaM-induced binding of CaMKII *in vitro*, as assessed by western analysis of GluN2B-bound CaMKII (\*\*\*p \< 0.001, unpaired two-tailed t test; WT, n = 5; mutant, n = 4).\
(F) HEK cells co-expressing labeled CaMKII and GluN2Bc WT or mutant, imaged before and after 5 min Ca^2+^ stimuli induced with ionomycin.\
(G) Quantification showed no significant difference in CaMKII/GluN2B colocalization (assessed by Pearson's correlation) compared to mCherry/GluN2B control(not significant \[NS\], p \> 0.05, one-way ANOVA; WT, n = 42, mutant, n = 38, mCh control, n = 36).\
(H) Quantification after ionomycin treatment showed a dramatic increase (two-way ANOVA followed by Bonferroni test) of CaMKII colocalization with GluN2B WT(\*\*\*p \< 0.001, compared to 0 min), but not with the GluN2B^ΔCaMKII^ mutant (^\#^p \< 0.05, compared to 0 min; ^\#\#\#^p \< 0.001, compared to WT).\
(I) The GluN2B^ΔCaMKII^ mutation allows normal DAPK1 binding (in absence of Ca^2+^/CaM) *in vitro*, as assessed by western analysis of GluN2B-bound DAPK1 (NS, p \> 0.05, unpaired two-tailed t test; n = 4).\
(J) HEK cells co-expressing labeled DAPK1 and GluN2Bc WT or mutant, imaged before and after 5 min Ca^2+^ stimuli induced with ionomycin.\
(K) Quantification showed indistinguishable DAPK1 colocalization with GluN2B WT and GluN2B^DCaMKII^ mutant (NS, p \> 0.05, Kruskal-Wallis followed by Bonferroni test; WT, n = 34, mutant, n = 41), compared to mCherry control (\*p \< 0.05; n = 36).\
(L) Quantification after ionomycin treatment showed the same dispersal of DAPK1 from GluN2B, with no differences detected between WT and GluN2B^ΔCaMKII^ mutant.](nihms-1548570-f0002){#F1}

![Selectivity of Neuroprotective Agents Targeting CaMKII versus DAPK1\
(A) CaMKII versus DAPK1 binding to GluN2B *in vitro* was reduced only by neuroprotective peptides designed to target the respective kinase, i.e., by 5 μM tatCN21 for CaMKII and by 50 μM tat2Bc for DAPK1. The neuroprotective DAPK1 small molecule inhibitor DAPK1-TC6 (TC; 1 μM) did not interfere with GluN2B binding for either kinase, as expected (\*p \< 0.05, one-way ANOVA followed by Dunnett's test; n = 4). Error bars indicate SEM in these panels. (B) CaMKII activity (measured by ATP depletion *in vitro*) was inhibited by tatCN21, but not by the DAPK1 inhibitor TC6 (each at 1 μM; p \< 0.05, Kruskal-Wallis followed by Dunn's test).](nihms-1548570-f0003){#F2}

![CaMKII Accumulates at Synaptic GluN2B after Excitotoxic Glutamate\
Error bars indicate SEM in all panels. Shown is the movement of CaMKII to excitatory versus inhibitory synapses (marked by PSD95, red, or gephyrin, blue) that is induced by excitotoxic glutamate stimuli. Scale bars indicate 10 μm. Statistical analysis was performed by paired t test (\*\*\*p \< 0.001; NS, p \> 0.05).\
(A and B) Overexpressed YFP-CaMKII (A) expressed in rat hippocampal neurons and endogenous CaMKII (B) in hippocampal neurons from WT mice (detected by an intrabody) moves to excitatory synapses.\
(C) This movement of endogenous CaMKII is blocked in neurons prepared from the GluN2B^ΔCaMKII^ mice.](nihms-1548570-f0004){#F3}

![DAPK1 Disperses from Dendritic Spines and Synaptic Fractions after *In Vitro* and *In Vivo* Insults\
Error bars indicate SEM in all panels.\
(A) Excitotoxic glutamate stimuli disperse mCh-DAPK1 from excitatory synapses (identified by PSD95 in red; \*\*\*p \< 0.001; NS, p \> 0.05; paired two-tailed t test). No change was observed at inhibitory synapses (identified by gephyrin in blue). Scale bar indicates 10 μm.\
(B--D) All quantifications of western blot analysis were normalized to actin staining, and fractions were verified by enrichment of PSD95 staining as synaptic marker (as shown in [Figure S3A](#SD1){ref-type="supplementary-material"}). Synaptic and extra-synaptic fractions were prepared by Triton X-100 extraction followed by ultracentrifugation, with the pellet containing synaptic protein. In order to highlight changes induced by the insults, values in all fractions were normalized to the levels detected before the insults.\
(B) Endogenous protein in a crude synaptic fraction from cultured hippocampal neurons before and after excitotoxic glutamate stimuli, analyzed by western blot. The amount of DAPK1 was significantly decreased 2 h after 5-min excitotoxic stimuli, compared to control (\*\*\*p \< 0.001, one-way ANOVA followed by Dunnett's test). The amount of CaMKII increased at each time point compared to control (\*p \< 0.05, \*\*p \< 0.005).\
(C) Endogenous protein in a crude synaptic versus extra-synaptic hippocampal fractions, analyzed by western blot. CA/CPR induced a decrease in synapticDAPK1 and an increase in extra-synaptic DAPK1, compared to sham (\*\*p \< 0.005, \*p \< 0.05, unpaired two-tailed t test). Ischemic injury also resulted in increased synaptic CaMKII and decreased extra-synaptic CaMKII, compared to sham (\*\*p \< 0.005, unpaired two-tailed t test).\
(D) Extra-synaptic GluN2B decreased and synaptic GluN2B increased following CA/CPR (\*\*p \< 0.005, \*\*\*p \< 0.001, unpaired two-tailed t test).](nihms-1548570-f0005){#F4}

  REAGENT or RESOURCE                                SOURCE                                 IDENTIFIER
  -------------------------------------------------- -------------------------------------- --------------------------------------------
  Antibodies                                                                                
  CaMKIIα                                            Made in House                          CBα2
  CaMKIIα pT286                                      Phospho-Solutions                      p1005--286; RRID:AB_2492051
  DAPK1                                              Sigma-Aldrich                          D1319; RRID:AB_1078622
  GluN2B                                             Cell Signaling                         D8E10; RRID:AB_2798506
  GluN2B pS1303                                      Millipore                              07--398; RRID:AB_310582
  GluN1                                              BD Biosciences                         556308; RRID:AB_2314954
  PSD-95                                             NeuroMab                               73--028; RRID:AB_10698024
  Beta Actin                                         Cell Signaling                         4970; RRID:AB_2223172
  Goat anti-Rabbit                                   GE Healthcare                          NA934V; RRID:AB_2722659
  Goat anti-Mouse                                    GE Healthcare                          NA931V; RRID:AB_772210
  Rabbit IgG                                         Jackson                                011--000--003; RRID:AB_2337118
  Chemicals, Peptides, and Recombinant Proteins                                             
  Papain                                             Worthington                            LS 03126
  Lipofectamine 2000                                 Invitrogen                             11668027
  B-27 supplement                                    GIBCO                                  17504044
  cOmplete protease inhibitor cocktail (EDTA-free)   Roche                                  1187380001
  Microcystin-LR                                     Calbiochem                             475815
  tat2BC                                             Chi Scientific; [@R43]                 N/A (custom peptide)
  DAPK-TC6                                           Tocris                                 19401
  tatCN21                                            Chi Scientific; [@R45]                 N/A (custom peptide)
  Glutathione-coated magnetic beads                  Pierce                                 78601
  Protein A-Sepharose beads                          RepliGen                               10--1003--01
  Critical Commercial Assays                                                                
  Pierce BCA protein assay                           Thermo-Fisher                          23225
  Deposited Data                                                                            
  Raw and analyzed data                              This paper                             <https://dx.doi.org/10.17632/5y58k87rw6.1>
  Experimental Models: Cell Lines                                                           
  Primary hippocampal cultures                       Laboratory of K. Ulrich Bayer          N/A
  HEK293 cells                                       ATCC                                   CRL-1573
  Experimental Models: Organisms/Strains                                                    
  Rat: Sprague-Dawley                                Charles River Labs                     N/A
  Mouse: Wild type: C57BL/6                          Charles River Labs                     N/A
  Mouse: GluN2B^ΔCaMKII^: C57BL/6                    [@R18]                                 N/A
  Recombinant DNA                                                                           
  CaMKIIα-FingR-GFP                                  Dr. Donald Arnold (USC) [@R27]         N/A
  PSD-95-FingR-GFP                                   [@R16]                                 Addgene \#46295
  Gephyrin-FingR-GFP                                 [@R16]                                 Addgene \#46296
  YFP-CaMKIIα                                        [@R9]                                  Addgene \#15214
  mCherry-DAPK1                                      [@R15]                                 Clonetech \#632524
  Software and Algorithms                                                                   
  Slidebook 6.0                                      Intelligent Imaging Innovations (3i)   RRID:SCR_014300
  Prism 7.0                                          Graphpad                               RRID: SCR_002798
  AlphaEase FC 4.0                                   Alpha Innotech                         N/A
  ImageJ                                             NIH                                    RRID:SCR_003070

###### Highlights

-   Disrupting CaMKII/GluN2B binding protects from neuronal injury after cardiac arrest

-   Neuroprotective CaMKII and DAPK1 inhibitors are selective for their respective kinase

-   CaMKII, but not DAPK1, accumulates at synaptic GluN2B during excitotoxic insults

-   Extra-synaptic GluN2B decreases during excitotoxic and ischemic insults
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